Overview

Raltitrexed in HIPEC

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the tolerance of patients with colorectal cancer to hyperthermic intraperitoneal chemotherapy with Raltitrexed, to determine the dose limiting toxicity and maximum tolerated dose.

Phase:

Phase 1

Details

Lead Sponsor:

Fudan University

Treatments:

Raltitrexed